抗真菌药敏试验与 AIDS 相关性隐球菌性脑膜炎的真菌清除率或生存率无关。
Antifungal Susceptibility Does Not Correlate With Fungal Clearance or Survival in AIDS-Associated Cryptococcal Meningitis.
机构信息
Guy's and St Thomas' NHS Trust, United Kingdom.
Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam.
出版信息
Clin Infect Dis. 2021 Oct 5;73(7):e2338-e2341. doi: 10.1093/cid/ciaa1544.
Abstract
We investigated the value of susceptibility testing in predicting response in AIDS-associated cryptococcal meningitis using clinical isolates from a randomized controlled trial of antifungal treatment (amphotericin monotherapy, amphotericin with flucytosine, or amphotericin with fluconazole). We found no correlation between antifungal susceptibility and either early or late survival, or fungal clearance.
摘要
我们研究了在一项抗真菌治疗（两性霉素单药治疗、两性霉素联合氟胞嘧啶治疗或两性霉素联合氟康唑治疗）的随机对照试验中，使用临床分离株进行药敏试验预测 AIDS 相关性隐球菌性脑膜炎反应的价值。我们发现抗真菌药敏性与早期或晚期生存率或真菌清除率之间没有相关性。
相似文献
1
Antifungal Susceptibility Does Not Correlate With Fungal Clearance or Survival in AIDS-Associated Cryptococcal Meningitis.抗真菌药敏试验与 AIDS 相关性隐球菌性脑膜炎的真菌清除率或生存率无关。
Clin Infect Dis. 2021 Oct 5;73(7):e2338-e2341. doi: 10.1093/cid/ciaa1544.
2
Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.乌干达艾滋病患者中新隐球菌分离株的分子流行病学及抗真菌药敏性
Diagn Microbiol Infect Dis. 1998 Nov;32(3):191-9. doi: 10.1016/s0732-8893(98)00095-9.
3
Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.艾滋病毒感染成人急性隐球菌性脑膜炎的治疗，重点关注资源有限的环境。
Cochrane Database Syst Rev. 2008 Oct 8(4):CD005647. doi: 10.1002/14651858.CD005647.pub2.
4
Amphotericin B with or without flucytosine followed by fluconazole as primary therapy for cryptococcal meningitis in patients with AIDS.两性霉素B联合或不联合氟胞嘧啶，随后使用氟康唑作为艾滋病患者隐球菌性脑膜炎的初始治疗。
Southeast Asian J Trop Med Public Health. 1996 Dec;27(4):719-23.
5
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.获得性免疫缺陷综合征相关隐球菌性脑膜炎的治疗。美国国立过敏和传染病研究所真菌病研究组及艾滋病临床试验组。
N Engl J Med. 1997 Jul 3;337(1):15-21. doi: 10.1056/NEJM199707033370103.
6
Therapy for cryptococcal meningitis in patients with AIDS.艾滋病患者隐球菌性脑膜炎的治疗
Clin Infect Dis. 1992 Mar;14 Suppl 1:S54-9. doi: 10.1093/clinids/14.supplement_1.s54.
7
Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi.氟胞嘧啶与高剂量氟康唑联合治疗与氟康唑单药治疗隐球菌性脑膜炎的随机试验：来自马拉维的研究。
Clin Infect Dis. 2010 Feb 1;50(3):338-44. doi: 10.1086/649861.
8
Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing.可通过氟康唑有效治疗的急性艾滋病相关隐球菌性脑膜炎患者的识别：抗真菌药敏试验的作用
Clin Infect Dis. 1996 Feb;22(2):322-8. doi: 10.1093/clinids/22.2.322.
9
Fluconazole-resistant cryptococcal meningitis.氟康唑耐药的隐球菌性脑膜炎
S Afr Med J. 2003 Jun;93(6):444.
10
Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.两性霉素B和氟康唑，一种用于治疗隐球菌性脑膜炎的有效联合疗法。
Antimicrob Agents Chemother. 2004 Mar;48(3):985-91. doi: 10.1128/AAC.48.3.985-991.2004.
引用本文的文献
1
Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List.隐球菌病——为世界卫生组织真菌优先病原体清单提供信息的系统评价。
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myae043.
2
Antifungal Resistance in Cryptococcal Infections.隐球菌感染中的抗真菌耐药性
Pathogens. 2024 Jan 29;13(2):128. doi: 10.3390/pathogens13020128.
3
Failure of Early Mycological Clearance in HIV-Negative Cryptococcal Meningitis.HIV阴性隐球菌性脑膜炎早期真菌清除失败
Open Forum Infect Dis. 2023 Mar 22;10(4):ofad158. doi: 10.1093/ofid/ofad158. eCollection 2023 Apr.
4
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?隐球菌性脑膜炎的治疗：我们已走到哪一步，未来又将如何？
Drugs. 2022 Aug;82(12):1237-1249. doi: 10.1007/s40265-022-01757-5. Epub 2022 Sep 16.
5
Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not?高剂量氟康唑联合氟胞嘧啶诱导治疗人类免疫缺陷病毒阴性隐球菌性脑膜炎患者：可行吗？
Mycoses. 2023 Jan;66(1):59-68. doi: 10.1111/myc.13528. Epub 2022 Sep 26.
6
Clinical utility of antifungal susceptibility testing.抗真菌药敏试验的临床应用
JAC Antimicrob Resist. 2022 Jun 28;4(3):dlac067. doi: 10.1093/jacamr/dlac067. eCollection 2022 Jun.
7
Early clinical and microbiological predictors of outcome in hospitalized patients with cryptococcal meningitis.住院患者隐球菌性脑膜炎的早期临床和微生物学预测因素。
BMC Infect Dis. 2022 Feb 9;22(1):138. doi: 10.1186/s12879-022-07118-7.
8
An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.一项关于他莫昔芬联合两性霉素 B 和氟康唑治疗隐球菌性脑膜炎的开放性随机对照试验。
Elife. 2021 Sep 28;10:e68929. doi: 10.7554/eLife.68929.
9
Aiming for a bull's-eye: Targeting antifungals to fungi with dectin-decorated liposomes.瞄准靶心：用树突状细胞受体修饰的脂质体靶向抗真菌药物。
PLoS Pathog. 2021 Jul 22;17(7):e1009699. doi: 10.1371/journal.ppat.1009699. eCollection 2021 Jul.
10
Cryptococcal Immune Reconstitution Inflammatory Syndrome: From Blood and Cerebrospinal Fluid Biomarkers to Treatment Approaches.隐球菌免疫重建炎症综合征：从血液和脑脊液生物标志物到治疗方法
Life (Basel). 2021 Jan 27;11(2):95. doi: 10.3390/life11020095.
本文引用的文献
1
Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for Antifungal Susceptibility Testing of Cryptococcus neoformans.新型隐球菌药敏试验中 MIC 测试条和 Sensititre YeastOne 与 CLSI 和 EUCAST 肉汤微量稀释参考方法的比较。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02261-19.
2
Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.氟康唑单药治疗隐球菌性脑膜炎初始治疗的选择并不理想，因为会出现耐药性。
mBio. 2019 Dec 3;10(6):e02575-19. doi: 10.1128/mBio.02575-19.
3
Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa.抗真菌药物联合治疗非洲隐球菌性脑膜炎。
N Engl J Med. 2018 Mar 15;378(11):1004-1017. doi: 10.1056/NEJMoa1710922.
4
Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.来自HIV感染和未感染患者的新型隐球菌和格特隐球菌分离株：抗真菌药敏性及隐球菌病的转归
Rev Inst Med Trop Sao Paulo. 2017;59:e49. doi: 10.1590/S1678-9946201759049. Epub 2017 Aug 3.
5
Physiological Differences in Cryptococcus neoformans Strains versus and Their Effects on Antifungal Susceptibility.新型隐球菌菌株的生理差异及其对抗真菌药敏性的影响
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02108-16. Print 2017 Mar.
6
Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients.免疫功能低下患者中对氟康唑最低抑菌浓度升高的新型隐球菌性脑膜炎的回顾性研究
Open Forum Infect Dis. 2016 Apr 7;3(2):ofw076. doi: 10.1093/ofid/ofw076. eCollection 2016 Apr.
7
Combination antifungal therapy for cryptococcal meningitis.抗真菌联合治疗隐球菌性脑膜炎。
N Engl J Med. 2013 Apr 4;368(14):1291-1302. doi: 10.1056/NEJMoa1110404.
8
Mixed infections and In Vivo evolution in the human fungal pathogen Cryptococcus neoformans.新型隐球菌中人真菌病原体的混合感染和体内进化。
mBio. 2010 May 18;1(1):e00091-10. doi: 10.1128/mBio.00091-10.
9
Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.新型隐球菌的氟康唑和两性霉素B药敏试验：针对265株来自HIV阳性患者且经过两个或更多月抗真菌治疗前后的分离株的最低抑菌浓度结果
Rev Iberoam Micol. 2009 Sep 30;26(3):194-7. doi: 10.1016/j.riam.2009.02.001. Epub 2009 Jul 18.
10
Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.新型隐球菌对氟康唑的异质性耐药是内在的，且与毒力相关。
Antimicrob Agents Chemother. 2009 Jul;53(7):2804-15. doi: 10.1128/AAC.00295-09. Epub 2009 May 4.
Zotero 插件